Su, HCQ early treatment study: 85% lower progression [p=0.006], 24% faster improvement [p=0.02], and 36% improved viral clearance [p=0.001] https://c19p.org/su
copied to clipboard
Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China
et al., BioScience Trends, doi:10.5582/bst.2020.03340
85% lower disease progression with early use of HCQ. Retrospective 616 patients in China showing adjusted progression HR 0.15, p = 0.006.
|
risk of progression, 84.9% lower, HR 0.15, p = 0.006, adjusted per study, binary logistic regression.
|
|
improvement time, 24.0% better, relative time 0.76, p = 0.02, adjusted per study, Cox proportional hazards.
|
|
risk of no viral clearance, 35.8% lower, HR 0.64, p = 0.001, Cox proportional hazards.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Su et al., 12/23/2020, retrospective, China, Asia, peer-reviewed, 9 authors, study period 20 January, 2020 - 30 April, 2020, dosage 400mg days 1-10, 400mg daily for 10-14 days.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.